Association of tenofovir exposure with kidney disease risk in HIV infection.
about
Updated US Public Health Service guidelines for the management of occupational exposures to human immunodeficiency virus and recommendations for postexposure prophylaxisHuman Immunodeficiency Virus as a Chronic Disease: Evaluation and Management of Nonacquired Immune Deficiency Syndrome-Defining ConditionsTenofovir effect on the kidneys of HIV-infected patients: a double-edged sword?Update on current management of chronic kidney disease in patients with HIV infectionHIV and kidney diseases: 35 years of history and consequencesThe end of AIDS: HIV infection as a chronic diseaseRole of traditional risk factors and antiretroviral drugs in the incidence of chronic kidney disease, ANRS CO3 Aquitaine cohort, France, 2004-2012Estimating kidney function in HIV-infected adults in Kenya: comparison to a direct measure of glomerular filtration rate by iohexol clearanceLow body weight in females is a risk factor for increased tenofovir exposure and drug-related adverse eventsScreening for decreased glomerular filtration rate and associated risk factors in a cohort of HIV-infected patients in a middle-income countryDevelopment and validation of a risk score for chronic kidney disease in HIV infection using prospective cohort data from the D:A:D studyRisk of Chronic Kidney Disease among Patients Developing Mild Renal Impairment during Tenofovir-Containing Antiretroviral TreatmentLong-Term Durability of Tenofovir-Based Antiretroviral Therapy in Relation to the Co-Administration of Other Drug Classes in Routine Clinical PracticeKidney Disease and HIV Infection.Association of tenofovir disoproxil fumarate with primary allograft survival in HIV-positive kidney transplant recipients.Changes in proteinuria and albuminuria with initiation of antiretroviral therapy: data from a randomized trial comparing tenofovir disoproxil fumarate/emtricitabine versus abacavir/lamivudine.Phase I/II study of the pharmacokinetics, safety and antiretroviral activity of tenofovir alafenamide, a new prodrug of the HIV reverse transcriptase inhibitor tenofovir, in HIV-infected adults.Application of marginal structural models in pharmacoepidemiologic studies: a systematic review.Is HIV a model of accelerated or accentuated aging?Incomplete reversibility of estimated glomerular filtration rate decline following tenofovir disoproxil fumarate exposureVitamin D deficiency aggravates nephrotoxicity, hypertension and dyslipidemia caused by tenofovir: role of oxidative stress and renin-angiotensin system.Evidence for risk stratification when monitoring for toxicities following initiation of combination antiretroviral therapyPolypharmacy in the HIV-infected older adult population.Race and other risk factors for incident proteinuria in a national cohort of HIV-infected veterans.A chronic kidney disease risk score to determine tenofovir safety in a prospective cohort of HIV-positive male veterans.Clinical practice guideline for the management of chronic kidney disease in patients infected with HIV: 2014 update by the HIV Medicine Association of the Infectious Diseases Society of America.Association of urine α1-microglobulin with kidney function decline and mortality in HIV-infected womenSwitching tenofovir/emtricitabine plus lopinavir/r to raltegravir plus Darunavir/r in patients with suppressed viral load did not result in improvement of renal function but could sustain viral suppression: a randomized multicenter trialThe association of adiposity with kidney function decline among HIV-infected adults: findings from the Fat Redistribution and Metabolic Changes in HIV Infection (FRAM) studyDevelopment of a definition for Rapid Progression (RP) of renal function in HIV-positive persons: the D:A:D studyA consensus statement on the renal monitoring of Australian patients receiving tenofovir based antiviral therapy for HIV/HBV infection.Changes in glomerular kidney function among HIV-1-uninfected men and women receiving emtricitabine-tenofovir disoproxil fumarate preexposure prophylaxis: a randomized clinical trialProtease Inhibitors and Renal Function in Patients with HIV Infection: a Systematic Review.Clinical outcomes of a combined HIV and renal clinic.Systematic Literature Review and Meta-Analysis of Renal Function in Human Immunodeficiency Virus (HIV)-Infected Patients Treated with Atazanavir (ATV)-Based Regimens.Renal Function Recovery and HIV Viral Suppression Following Tenofovir Discontinuation for Renal Impairment.Low Incidence of Renal Dysfunction among HIV-Infected Patients on a Tenofovir-Based First Line Antiretroviral Treatment Regimen in Myanmar.Long-Term Follow-Up of Proteinuria and Estimated Glomerular Filtration Rate in HIV-Infected Patients with Tubular Proteinuria.Proximal tubular dysfunction and kidney injury associated with tenofovir in HIV patients: a case series.Targeted spontaneous reporting of suspected renal toxicity in patients undergoing highly active anti-retroviral therapy in two public health facilities in Uganda.
P2860
Q22242951-A6F00542-8FC9-41B8-829E-0B837A86491CQ26740117-F123B546-6795-4416-A8D5-441ADE2C56E1Q26995852-30311418-36D8-47DB-A9D6-75E9FBBB644AQ27691460-4851AA80-BA3C-4063-9EA5-B70F7383C7FCQ28069641-7A99C0B0-7FC0-4632-846A-8D26CDBBC9F6Q28300749-F924F36C-CBEB-4938-918D-5C0E2F5CEF78Q28533843-EDBC2343-ED7C-4318-96BF-68C1B2B9971CQ28535213-067735F0-ADE5-4B81-99F9-5CF21F0D2FEAQ28535587-072F61D9-20C5-4ACE-9EA7-A7870FE387DEQ28541930-432DD88C-8505-48F4-BB31-EADA1B2D7CECQ28545222-09C4FDE5-44D2-4C85-BCF9-1CD31348A7ECQ28554081-C60354FC-6108-4AB1-86FB-448642F842C3Q28554567-C5E85A76-C7EF-480C-ACA1-610579271931Q30234837-11EDF76E-B814-4FBF-A370-7FBE4774DA60Q30252384-A68193B0-0057-4696-9BE5-053B8473E9B2Q30842348-4EAE3197-5EE8-4AFE-9C18-69A314A26B32Q33460754-F5F8EF33-AFC5-4CE2-AD6F-0887BC89EF7FQ33707284-6B3E9738-6222-465A-9589-56030C8B5B4FQ33792651-BA492A52-D352-46E3-81E7-F30BEBE39C30Q33880241-43F51A58-7D34-458F-A8A0-EDBA13CF7075Q33928535-C6C57D9C-D16B-44D2-97F7-9FA11A6EEF08Q33939760-409B0692-EB1B-400F-9B83-99457D3F5A9DQ34037407-CBE580CB-4E70-4864-8D12-DE76197A92A9Q34173588-5E0813E0-F2CF-4E02-952E-3F0F647669A4Q34301401-B6FE6360-BEB1-41F5-909E-6122CF2ACFECQ34736194-43A87654-76E7-43CC-9243-A429B434DB8DQ34828514-47225EB1-F4C4-457A-B7EE-C404C6D1D7F4Q34952127-DFDF7CD6-0022-4621-90B4-36A219482242Q35060772-99E9ABB8-859E-4B40-949D-2502E30B470AQ35130736-204BF18B-833B-4A5A-995E-689C2A1FBCFFQ35149475-29182E48-AF4D-49E8-ADBC-CACF21BE995AQ35163040-8A6C45FC-7363-4BE8-AE5E-4E267FC58E3EQ35186842-82D913C3-0A58-40BE-AD79-B4513DBC359AQ35453074-1CD39A01-AE0B-4DC5-9D74-E6448665EFCFQ35566732-8BB0C323-E5B7-4932-9546-80B848C5D69BQ35748339-E7A9474B-9CE1-402A-9531-614423FCE236Q35753540-D0A3299E-D601-4C0A-B618-5124D819DEBDQ35841996-6D866148-F274-4B40-9362-7098E90D68DEQ35891568-AEE561D2-C73E-4360-ADB6-2EF167473BF9Q35981062-C224C5EB-4765-448E-A186-1FF68DD9CDEA
P2860
Association of tenofovir exposure with kidney disease risk in HIV infection.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on April 2012
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Association of tenofovir exposure with kidney disease risk in HIV infection.
@en
Association of tenofovir exposure with kidney disease risk in HIV infection.
@nl
type
label
Association of tenofovir exposure with kidney disease risk in HIV infection.
@en
Association of tenofovir exposure with kidney disease risk in HIV infection.
@nl
prefLabel
Association of tenofovir exposure with kidney disease risk in HIV infection.
@en
Association of tenofovir exposure with kidney disease risk in HIV infection.
@nl
P2093
P2860
P1433
P1476
Association of tenofovir exposure with kidney disease risk in HIV infection.
@en
P2093
Andy I Choi
Carl Grunfeld
Michelle Estrella
Rebecca Scherzer
Yongmei Li
P2860
P304
P356
10.1097/QAD.0B013E328351F68F
P407
P577
2012-04-01T00:00:00Z